Sarepta (SRPT) PT Raised to $25 at Wedbush on Go-Ahead for Eteplirsen NDA
Tweet Send to a Friend
Wedbush analyst Heather Behanna raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $25.00 (from $16.00) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
